key: cord-0988396-dww0xymd
authors: Dey, Debayan; Ramakumar, Suryanarayanarao; Conn, Graeme L.
title: Targeted redesign of suramin analogs for novel antimicrobial lead development
date: 2021-08-27
journal: bioRxiv
DOI: 10.1101/2021.05.17.444489
sha: 2cfb9474e5e71d4a21982f2fd750391ad6ef0be7
doc_id: 988396
cord_uid: dww0xymd

The emergence of new viral infections and drug resistant bacteria urgently necessitates expedient therapeutic development. Repurposing and redesign of existing drugs against different targets is one potential way in which to accelerate this process. Suramin was initially developed as a successful anti-parasitic drug but has also shown promising antiviral and antibacterial activities. However, due to its high conformational flexibility and negative charge, suramin is considered quite promiscuous towards positively charged sites within nucleic acid binding proteins. Although some suramin analogs have been developed against specific targets, only limited structure activity relationship (SAR) studies were performed, and virtual screening has yet to be used to identify more specific inhibitor(s) based on its scaffold. Using available structures, we investigated suramin’s target diversity, confirming that suramin preferentially binds to protein pockets which are both positively charged and enriched in aromatic or leucine residues. Further, suramin’s high conformational flexibility allows adaptation to structurally diverse binding surfaces. From this platform, we developed a framework for structure- and docking-guided elaboration of suramin analog scaffolds using virtual screening of suramin and heparin analogs against a panel of diverse therapeutically relevant viral and bacterial protein targets. Use of this new framework to design potentially specific suramin analogs is exemplified using the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) and nucleocapsid protein, identifying leads that might inhibit a wide range of coronaviruses. The approach presented here establishes a computational framework for designing suramin analogs against different bacterial and viral targets and repurposing existing drugs for more specific inhibitory activity. For Table of Contents Use Only Table of Contents Graphic

5 analogs to be more conformationally selective than suramin and to have greater target specificity. 68 Finally, SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) and nucleocapsid are used to 69 exemplify the process of suramin analog redesign to generate novel analogs with the potential to 70 bind with higher affinity and target specificity. Evolutionary analyses suggest that the optimized 71 leads could potentially inhibit a wide range of coronaviruses 24 . This study thus sets out a 72 computational framework using structure-and docking-guided ligand elaboration that can 73 support redesign and repurposing existing antimicrobials for new, specific inhibitory activities. Structural basis for suramin protein target site diversity 77 Suramin is a C2 symmetric molecule with each half comprised of a trisulfonated naphthyl ring 78 with negative charge at physiological pH, connected via amide linkages to toluene and phenyl 79 rings (Fig. 1A) . Suramin is highly flexible with a total of 10 rotatable bonds ( Fig. 1A ; α 1-5 and 80 α 1'-5' ) and no substituent groups on the four central rings that might otherwise restrict its 81 conformational freedom. This flexibility, and thus conformational adaptability, is likely a key 82 factor in suramin's ability to interact with diverse target sites in many proteins, but also its high 83 off-target binding. Similarly, another polyanionic class of molecules similar to suramin, the 84 glycosaminoglycans (GAGs) such as heparin (Fig. 1B) , can bind multiple diverse protein targets 85 but also suffer the limitation of high off-target binding.

To begin defining the residue preferences in suramin binding pockets, we examined 87 structures of several suramin complexes with diverse proteins (Table S1 ). These structures stacking interactions, including residues Asn66, Lys67 and Arg95 with the trisulfo-naphthyl ring, 121 and Arg64, Thr63, Gly65, Phe177 and Pro127 the two central rings (Fig. S1B) . Thus, visual 122 inspection of these viral protein structures reveals overall consistent trends in suramin's binding 123 pocket residue interaction preferences with other proteins of diverse origin and function.

More detailed analyses of available suramin-bound protein structures reveal consistent 125 features in the binding pocket physicochemical composition, including strong enrichment of 126 specific residues (Fig. 1G) . Positively charged Lys and Arg are highly enriched in the pocket 127 compared to the full protein (25% and 15%, respectively, of all interacting residues), while His is 128 more modestly enriched (5%), but, as noted, can make both aromatic stacking and charged 129 interactions. The absence of negatively charged residues (~1.5% combined) also points towards 130 suramin's strong preference for positively charged binding regions, such as nucleic acid binding 131 sites. In total, polar residues are slightly less favored (~12 % total) as compared to aliphatic 132 hydrophobic residues (~14%), with a marked preference for Leu (10.6 %) among the latter group 133 (Fig. 1G) . This may be due to leucine's aliphatic stacking potential with the aromatic rings of 134 suramin. Aromatic residues (Trp, Tyr and Phe; together ~25% of total) are also strongly enriched 135 in suramin binding sites.

Suramin's binding promiscuity for diverse protein targets is likely underpinned by its 137 high inherent conformational flexibility, as revealed by superposition of protein-bound suramin 138 molecules using one trisulfo-naphthyl ring (Fig. 1H) rational design of novel analogs with improved affinity and specificity towards a desired target.

We devised a strategy to accomplish this goal using docking studies with suramin and heparin 163 analogs and using docking poses of the latter set of ligands to guide design of new suramin 164 analogs with substituents positioned to make additional protein target-specific interactions ( Fig.   165 2). 166 Nucleic acid binding proteins in bacteria and viruses play crucial roles in the processing PubChem search which identified ~2,000 and ~10,000 analogs of suramin and heparin, 198 respectively ( Fig. 2A) . 199 Using the protein target panel and suramin/ heparin analog sets, high-throughput virtual in distribution and average score for each protein target (Fig. 3A,B) . Among the bacterial 203 proteins, suramin analogs bind on average more tightly to Fis and TsnR (mean binding score -5.7 204 12 and -5.9 kcal/mol, respectively) compared to HU and RecA (-5.1 and -4.6 kcal/mol, respectively; 205 Fig 3A) . HIV protein gp120 was predicted to be bound less tightly with a mean score of -3.6 206 kcal/mol, whereas both suramin and heparin analogs docked viral RdRp with comparatively 207 higher score (Fig. 3A,B) . 208 Among the top 100 scoring suramin and heparin analogs identified by HTVS, more than 209 ~50% of these ligands bind to only a single protein among the nine targets (Fig. 3C,D) . 210 Approximately 30% of the remaining ligands in each set bind to only two or three receptors, with Table S3 ) are all markedly more conformationally rigid than suramin, 260 due to the diazene linker between the naphthyl rings. Sur-1 has only four rotatable bonds with a 261 single low energy conformation (Fig. 4B) , compared to 10 rotatable bonds and 116 low energy for optimal geometric placement of additional polar groups to enhance interaction within the 285 binding site (Fig. 4A,D) . Results for further details). Specifically, we identified sites for targeted redesign of Sur-6 (using HIV gp120 (6IEQ) binds to smaller analogs than the other targets with the highest docking score 298 to Sur-22 and sites for targeted redesign identified by docking of Hep-51 ( Fig. S3E-H) . 299 Similarly, for norovirus RdRp (Fig. S4A-D) and bunyavirus nucleocapsid (Fig. S4E, F with an RNA binding tunnel that presents a potential site for drug targeting (Fig. S5A,B) , and conformationally restricted diazene linker (Fig. 5B) . Two other similarly high-scoring ligands,

Sur-37 and Sur-38, were also identified ( and the proximal sulfo-naphthyl ring with Tyr546 and Asn497 (Fig. 5A, B) . 320 Using the Hep-58 binding pose, four positions for additional substitutions in Sur-36 were 321 identified (Fig. S5D) The same process was also applied to the SARS-CoV-2 nucleocapsid RNA binding 353 domain 29 which has a shallow positively charged surface (Fig. S5E-G and Arg89 (Fig. 5D, E) . Our heparin screen also identified Hep-59 as binding to the same region, 362 revealing potential for extending the Sur-31 scaffold at several sites (indicated * in Fig. S5H ). 363 Again, using docking-guided elaboration, one naphthyl ring was replaced by two sulfonyl- increased H-bonding and electrostatic interactions compared to Sur-31 ( Fig. 5F and S6B) . 373 

This process thus identified an initial suramin analog for both SARS-CoV-2 protein and HCoV-HKU1 (Fig. 6A, B; Fig S7) . The conservation of the RdRp binding site also extends 387 to α -coronavirus family members of bat origin, which originated the human pathogens HCoV-

229E and HCoV-NL63 (Fig. 6A, B) . More broadly, the generally strong conservation in each reasonable timescale. Among these approaches, the level of precision (e.g., HTVS vs SP Glide) also 407 dictate the speed of docking calculations and thus our choice of initial HTVS followed by SP Glide 408 rescoring ( Fig. 2 and Fig. 3E,F) . However, even compound rankings from the more accurate SP Glide 

To assess the utility of incorporating MM-GBSA calculations, we first used experimental data for 418 suramin analogs targeted to SARS-CoV-2 RdRp, which were published during the course of this work 21 .

First, SP Glide docking and MM-GBSA calculations were performed for suramin and five of the reported 420 compounds 21 and both methods showed good correlation with observed activity, particularly for MM-

GBSA (R 2 0.63 for SP Glide and 0.90 for MM-GBSA; (Fig. 7A, B) . Glide score (Fig. S8B) . Similarly, heparanase inhibitors which have potential use in inflammatory 449 diseases, were reported based on suramin scaffold 40 . Our analysis (Fig. S8C ) again showed no correlation 450 between SP Glide and measured activity, whereas MM-GBSA was highly predictive (R 2 = 0.92) of IC 50 ,

except for a small group of ligands (red points in Fig. S8C) . We speculate that these outliers are a result 452 of differential effect of those ligands on the target; for example, optimal binding of these ligands might activity data for other protein targets, we also showed that MM-GBSA calculations consistently 514 correlate well with experimental data. These studies thus suggest that incorporation of MM-

GBSA at some stage of our computational pipeline (e.g., either prior to, or during lead analog re-516 design; Fig. 2C ), can at a minimum enhance confidence in a ligand set identified by SP Glide, 517 while for other targets its use may be essential. We speculate that the flexibility of the target,

which is better modeled in MM-GBSA as compared to SP Glide scores, can be essential for 519 success with some targets. However, initial selection of lead compounds from large libraries, can 520 still reliably use much faster HTVS and SP Glide scoring, followed by MM-GBSA (or other 521 more sophisticated approaches) to support later stages of lead optimization.

Our studies also identified the potential to target SARS-CoV-2 nucleocapsid with 523 suramin analogs and proposed analogs possessing enhanced affinity and specificity. This 524 approach could also be applied to the 3CL protease which was recently identified as another 525 possible suramin binding target 43 . Our phylogenetic and evolutionary analyses also suggest that 526 the suramin binding pockets are evolutionary conserved in related coronavirus RdRp and 527 nucleocapsid proteins which could make these suramin analogs more broadly applicable 528 therapeutics against this group of viral pathogens.

In summary, this study has defined the basis of suramin promiscuity and the nature of its 530 preferred protein target binding sites and established a computational pipeline (Fig. 2) Fig S9) . 535 These properties can be readily exploited for future fragment-based designs of suramin-like 536 inhibitors of viral and bacterial nucleic acid binding proteins. As such, our strategy offers the 537 possibility for expedient design of novel suramin analogs with improved properties and efficacy 538 for synthesis and experimental confirmation of their potential as novel lead antimicrobials. 

To prepare each protein ("receptor") for ligand docking, hydrogen atoms were added, and 550 the structure energy minimized using the Protein Preparation Wizard in Schrödinger Software.

The docking grid location was determined by analysis of the nucleic acid binding region of each Tables   Table S1 . Protein crystal structures with bound suramin and suramin analogs. Table S2 . Ligands used as database search query for suramin and heparin analogs. Table S3 . Glide SP docking score of suramin analogs to bacterial and viral targets. Table S4 . Glide SP docking score of heparin analogs to bacterial and viral targets.

Rapid Repurposing of Drugs for COVID-19

SARS-Cov-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus

Antiinflammatory Effects of Dexamethasone Are Partly Dependent on Induction of Dual Specificity Phosphatase 1

A Critical Evaluation of Glucocorticoids in the Management of Severe COVID-19

Ivermectin: A Systematic Review from Antiviral Effects to COVID-19 Complementary Regimen

Suramin Inhibits SARS-Cov-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle

Human African Trypanosomiasis

Suramin: With Special Reference to Onchocerciasis

The Trypanocidal Drug Suramin and Other Trypan Blue Mimetics Are Inhibitors of Pyruvate Kinases and Bind to the Adenosine Site

Suramin and Suramin Analogues Inhibit Merozoite Surface Protein-1 Secondary Processing and Erythrocyte Invasion by the Malaria Parasite Plasmodium Falciparum

100 Years of Suramin

Synthetic Soluble Analogs of Galactosylceramide (Galcer) Bind to the V3 Domain of HIV-1 Gp120 and Inhibit HIV-1-Induced Fusion and Entry

The Polysulfonated Compound Suramin Blocks Adsorption and Lateral Difusion of Herpes Simplex Virus Type-1 in Vero Cells

Suramin Blocks Hepatitis C Binding to Human Hepatoma Cells in Vitro

Dengue Virus Infectivity Depends on Envelope Protein Binding to Target Cell Heparan Sulfate

Suramin Interacts with the Positively Charged Region Surrounding the 5-Fold Axis of the EV-A71 Capsid and Inhibits Multiple Enterovirus A

Suramin Inhibits Zika Virus Replication by Interfering with Virus Attachment and Release of Infectious Particles

Structure-Based Inhibition of Norovirus RNA-Dependent RNA Polymerases

Suramin Inhibits Chikungunya Virus Replication through Multiple Mechanisms

Structural Basis for Inhibition of the SARS-Cov-2 RNA Polymerase by Suramin

Synthesis and Structure-Activity Relationships of Suramin-Derived P2Y11 Receptor Antagonists with Nanomolar Potency

Structure-Activity Studies on Suramin Analogues as Inhibitors of NAD+-Dependent Histone Deacetylases (Sirtuins)

On the Origin of SARS-Cov-2: Did Cell Culture Experiments Lead to Increased Virulence of the Progenitor Virus for Humans

Inhibition of Myotoxic Activity of Bothrops Asper Myotoxin Ii by the Anti-Trypanosomal Drug Suramin

Structural Basis of Inhibition of the Human NAD+-Dependent Deacetylase SIRT5 by Suramin

Small-Molecule Modulators of Methyl-Lysine Binding for the CBX7 Chromodomain

Structure of Severe Fever with Thrombocytopenia Syndrome Virus Nucleocapsid Protein in Complex with Suramin Reveals Therapeutic Potential

Nucleocapsid Protein RNA Binding Domain Reveals Potential Unique Drug Targeting Sites

Suramin Inhibits Binding of the V3 Region of HIV-1 Envelope Glycoprotein Gp120 to Galactosylceramide, the Receptor for HIV-1 Gp120 on Human Colon Epithelial Cells

Bacterial Nucleoid-Associated Proteins, Nucleoid Structure and Gene Expression

The Shape of the DNA Minor Groove Directs Binding by the DNA-Bending Protein Fis

Targeting Mycobacterium Tuberculosis Nucleoid-Associated Protein HU with Structure-Based Inhibitors

Structural and Evolutionary Analyses Reveal Determinants of DNA Binding Specificities of Nucleoid-Associated Proteins HU and IHF

Suramin Is a Potent and Selective Inhibitor of Mycobacterium Tuberculosis RecA Protein and the SOS Response: RecA as a Potential Target for Antibacterial Drug Discovery

Structure of the Thiostrepton Resistance Methyltransferase.S-Adenosyl-L-Methionine Complex and Its Interaction with Ribosomal RNA

Structural and Biochemical Characterization of the Nsp12-Nsp7-Nsp8 Core Polymerase Complex from SARS-Cov-2

Free Energy Via Molecular Simulation: Applications to Chemical and Biomolecular Systems

The Anti-Parasitic Agent Suramin and Several of Its Analogues Are Inhibitors of the DNA Binding Protein Mcm10

New Classes of Potent Heparanase Inhibitors from Ligand-Based Virtual Screening

Design, Synthesis and Biological Evaluation of Suramin-Derived Dual Antagonists of the Proinflammatory G Protein-Coupled Receptors P2y2 and Gpr17

Falcipain-2 Inhibition by Suramin and Suramin Analogues

Identification of SARS-Cov-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening

Confgen: A Conformational Search Method for Efficient Generation of Bioactive Conformers

Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy

Antibiotic Substrate Selectivity of Pseudomonas Aeruginosa MexY and MexB Efflux Systems Is Determined by a Goldilocks Affinity

Large-Scale Systematic Analysis of 2D Fingerprint Methods and Parameters to Improve Virtual Screening Enrichments

Cd-Hit: Accelerated for Clustering the Next-Generation Sequencing Data

MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets

ConSurf 2016: An Improved Methodology to Estimate and Visualize Evolutionary Conservation in Macromolecules

Additional underlying data from these studies beyond those provided in the Supplementary Materials will be made available on request by the authors.

Debayan Dey, email: debayan.dey@emory.edu or Graeme L. Conn, email: gconn@emory.edu

DD, SR and GLC conceptualized the project. DD and GLC wrote the draft. All authors have given approval to the final version of the manuscript.

None ACKNOWLEDGEMENT We thank Dr. William Wuest for comments on the manuscript and members of the Conn lab for discussions and comment through the course of this work.